Tradestie Institutional Equity Comparison Engine
DXCM vs EW โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DXCM Overall Edge
DXCM Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DexCom, Inc. (DXCM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DXCM trades at 25.3x Forward P/E with 24.0% operating margin (+11.2% YoY revenue) versus EW at 30.1x Forward P/E and 28.8% operating margin (+10.5% YoY). In options structure, DXCM sits in CONSOLIDATION (15th %ile IV; Dealer Gamma Walls on Pro) against EW sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
DXCM
DXCM 25.3x vs EW 30.1x Fwd P/E
Growth & Margin Winner
DXCM
Op Margin 24.0% vs 28.8% ยท YoY +11.2% vs +10.5%
Momentum & Technical Winner
DXCM
1Y +32.8% vs +18.4% ยท 52W Pos 63% vs 82%
Options & Structure Winner
DXCM
CONSOLIDATION (15th %ile IV) vs UNCLASSIFIED (100th %ile IV)
DXCM
NASDAQ
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap
$29.9B
1M Return
+1.28%
1Y Return
+32.8%
Forward P/E
25.3x
Unified AI Score
50.8 / 100
HOLD
Tech 49.0
Fund 56.0
Flow 68.0
Mom 54.0
EW
NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$101.85
-1.95% 1D
Market Cap
$59.7B
1M Return
+13.05%
1Y Return
+18.4%
Forward P/E
30.1x
Unified AI Score
40.0 / 100
SELL
Tech 24.0
Fund 43.0
Flow 55.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DXCM +32.8%
EW +18.4%
Spread: +14.4 pp (DXCM Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DXCM Revenue | EW Revenue | DXCM Op. Margin | EW Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $1.03B | $3.72B | -18.1% | 20.1% | EW |
| FY2019 | $1.48B | $4.35B | 9.6% | 26.4% | EW |
| FY2020 | $1.93B | $4.39B | 15.5% | 20.5% | EW |
| FY2021 | $2.45B | $5.23B | 10.9% | 32.3% | EW |
| FY2022 | $2.91B | $4.46B | 13.4% | 33.6% | EW |
| FY2023 | $3.62B | $5.01B | 16.5% | 26.1% | EW |
| FY2024 | $4.03B | $5.44B | 14.9% | 25.3% | EW |
| FY2025 | $4.66B | $6.07B | 19.6% | 20.8% | EW |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DXCM | EW | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $29.9B | $59.7B | Larger Scale | EW |
| Trailing P/E Ratio Valuation | 31.6x | 60.4x | Lower Multiple | DXCM |
| Forward P/E Ratio Valuation | 25.3x | 30.1x | Lower Multiple | DXCM |
| Revenue Growth (YoY) Growth | +11.2% | +10.5% | Higher Growth | DXCM |
| Operating Margin (TTM) Profitability | 24.0% | 28.8% | Higher Margin | EW |
| Net Profit Margin Profitability | 19.4% | 15.3% | Higher Margin | DXCM |
| Return on Equity (ROE) Capital Efficiency | 37.7% | 9.3% | Higher ROE | DXCM |
| 52-Week Range Position Momentum | 63% ($57โ$93) | 82% ($75โ$108) | Stronger Trend | EW |
| Beta / 30D Volatility Risk Regime | 0.59ฮฒ ยท 43% Vol | 0.43ฮฒ ยท 27% Vol | Lower Realized Risk | EW |
| Unified Institutional Score Composite Signal | 50.8 / 100 (HOLD) | 40.0 / 100 (SELL) | Higher Composite | DXCM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DXCM vs EW Buy Guide
DXCM
CONSOLIDATION
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
15th %ile
IV Regime
Compressed (<25th %ile)
EW
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DXCM nor EW registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.